Drugs / MG-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02019056 | Nov 2010 → Dec 2014 | alcoholic fatty liver disease, alcoholic hepatitis | PharmaKing | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-02 | Glenmark Pharmaceuticals Ltd. India | Glenmark to launch Eribulin Mesylate Injection 1 mg-2 mL (0.5 mg-mL) Single-Dose Vials glenmarkpharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02019056 ↗ |